Precision medicine for prostate cancer: An international perspective.

Autor: Hamid AA; Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Surgery, University of Melbourne, Melbourne, Australia. Electronic address: hamida1@mskcc.org., Sweeney CJ; South Australian Immunogenomics Cancer Institute, Adelaide, Australia., Hovens C; Department of Surgery, University of Melbourne, Melbourne, Australia., Corcoran N; Department of Surgery, University of Melbourne, Melbourne, Australia., Azad AA; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Jazyk: angličtina
Zdroj: Urologic oncology [Urol Oncol] 2024 Apr 12. Date of Electronic Publication: 2024 Apr 12.
DOI: 10.1016/j.urolonc.2024.02.004
Abstrakt: Greater personalization of cancer medicine continues to shape therapy development and patient selection accordingly. The treatment of prostate cancer has evolved considerably since the discovery of androgen deprivation therapy. The comprehensive profiling of the prostate cancer genome has mapped the targetable molecular landscape of the disease and identified opportunities for the implementation of novel and combination therapies. In this review, we provide an overview of the molecular biology of prostate cancer and tools developed to aid prognostication and prediction of therapy benefit. Modern treatment of advanced prostate cancer is reviewed as a paradigm of increasing precision-informed approach to patient care, and must be considered on a global scale with respect to the state of science and care delivery.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: